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Abstract
Down syndrome, which arises in individuals carrying an extra copy of chromosome 21, is 
associated with a greatly increased risk of early-onset Alzheimer disease. It is thought that this risk 
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is conferred by the presence of three copies of the gene encoding amyloid precursor protein (APP) 
— an Alzheimer disease risk factor — although the possession of extra copies of other 
chromosome 21 genes may also play a part. Further study of the mechanisms underlying the 
development of Alzheimer disease in people with Down syndrome could provide insights into the 
mechanisms that cause dementia in the general population.
Down syndrome (DS) is a complex, highly variable disorder that arises from trisomy of 
chromosome 21. It was one of the first chromosomal disorders to be identified1 and occurs 
with an incidence of approximately 1 in 800 births2. Its prevalence within a given 
population is influenced by infant mortality rates, access to health care, termination rates, 
average maternal age3 and life expectancy. Indeed, despite the increased availability of 
prenatal diagnosis and access to the option of termination, the global prevalence of DS is 
rising because of improvements in life expectancy: the number of adults with DS aged over 
40 years has doubled in northern Europe since 1990 and, in the United Kingdom, one-third 
of the estimated 40,000 people with DS are thought to be over 40 years of age4.
DS is the most common form of intellectual disability. In addition to the features that are 
found in everyone with the disorder, such as the characteristic facial dysmorphology, there 
are many DS-associated phenotypes that have variable penetrance and severity. For 
example, approximately 40% of individuals with DS have heart malformations (usually 
atrioventricular septal defects)5. A key feature of DS is a striking propensity to develop 
early-onset Alzheimer disease (EOAD). Complete trisomy of chromosome 21 universally 
causes the development of amyloid plaques and neurofibrillary tangles (NFTs), which are 
typical characteristics of AD brain pathology, by the age of 40, and approximately two-
thirds of individuals with DS develop dementia by the age of 60 (REFS 6,7). However, rates 
of dementia do not reach 100%, even in older individuals, suggesting that some individuals 
with DS are protected from the onset of AD (FIG. 1).
All of the features of DS arise because of aberrant dosages of coding and/or non-coding 
sequences present on chromosome 21. Among these sequences, the gene encoding amyloid 
precursor protein (APP) is thought to have a key role in the pathology of AD. The additional 
copy of APP may drive the development of AD in individuals with DS (AD-DS) by 
increasing the levels of amyloid-β (Aβ), a cleavage product of APP that misfolds and 
accumulates in the brain in people with AD. Consistent with this hypothesis, individuals 
with small internal chromosome 21 duplications that result in three copies of APP — a rare 
familial trait known as duplication of APP (Dup-APP) — also develop EOAD8–15. 
Conversely, partial trisomy of chromosome 21 that does not result in the presence of an 
extra APP does not lead to AD16,17. Several additional genes on chromosome 21 are 
proposed to modulate the course of AD-DS, but further work is required to determine their 
role and relative importance.
The aim of this Opinion article is to present an overview of clinical and pathological features 
of AD-DS and, by comparing these to other forms of AD (particularly AD induced by Dup-
APP), to highlight shared genetic, pathogenic and protective mechanisms and to discuss key 
future research areas. Similarities in the aetiologies of AD-DS and other forms of AD may 
highlight common disease mechanisms, whereas differences between these forms of AD 
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may help to identify novel genes and pathways that are important in particular aspects of 
AD. Recent advances in genetic, cellular and neuroimaging technologies have provided the 
means to comprehensively explore the link between AD and DS, and recent improvements 
in the life expectancy of people who have DS mean that more individuals than ever before 
are developing AD-DS. The growing interest in AD-DS is long overdue, given the high AD 
burden in the DS population, and it is likely that research into AD-DS may also lead to a 
better understanding of AD in the general population.
Prevalence of AD-DS
A loss of cognitive function in middle-aged adults with DS was described soon after the 
identification of the syndrome18, and it was later shown that this loss resulted from the onset 
of AD dementia. As indicated above, AD is now common in adults with DS who are over 
the age of 40 years and, like other genetic forms of EOAD, develops two to three decades 
earlier in individuals with DS than in the general population. Data describing the prevalence 
of AD-DS vary between studies because of diagnostic issues, such as the presence of 
variable premorbid deficits, and survey methodology19. However, the prevalence of AD in 
people who have DS is <5% under the age of 40 (REF. 20) and then roughly doubles with 
each 5-year interval up to the age of 60. Hence, approximately 5–15% of individuals with 
DS aged 40–49 years and >30% of those aged 50–59 years experience significant cognitive 
decline, indicating dementia (FIG. 1). Thus, as with AD in the general population, age is a 
strong independent risk factor for AD-DS21. By the age of 65, 68–80% of individuals with 
DS have been shown to have developed dementia6,7 (FIG. 1; Supplementary information S1 
(table)), and some studies of institutionalized people with DS suggest that rates are even 
higher6,20,22. However, not all older individuals with DS develop dementia, with some 
reaching their 70s without significant symptoms of AD despite having full trisomy of 
chromosome 21 (REF. 23). After the age of 60, prevalence rates decrease, probably owing 
to the high mortality rate that is associated with dementia21.
The average age at which menopause begins in women with DS correlates with the age of 
onset of dementia24–26; however, unlike the incidence of AD in euploid individuals, gender 
does not affect the incidence of AD-DS20,21. The reasons for this difference between the two 
populations are unknown, although it is possible that trisomy may cause changes in 
hormonal or cardiovascular biology that alter AD risk. The influence of gender on dementia 
development is complex in both the DS and euploid populations, and warrants more-
extensive, longitudinal, population-based study.
Although increased levels of triglycerides and total body fat and low rates of exercise are 
reported in adults with DS27, and higher cholesterol levels have been associated with the 
risk of developing dementia in this group28, individuals with DS have lower rates of other 
cardiovascular risk factors — including hypertension, atherosclerosis and smoking29,30 — 
that are thought to contribute to the development of dementia in the general population31. 
Further studies are required to understand how trisomy alters the biology of the 
cardiovascular system and what impact this has on neurodegeneration in people who have 
DS.
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The brain reserve hypothesis is based on the observation that, in the general population, 
individuals with higher levels of education and/or more-active social and intellectual 
lifestyles have a lower risk of developing dementia32. The hypothesis predicts that 
individuals with more-severe premorbid cognitive impairment will have an increased risk of 
developing dementia. However, no convincing relationship between severity of intellectual 
disability (or intelligence quotient (IQ) score) and risk of AD has been found in people with 
DS33, possibly because of diagnostic difficulties in those with severe impairments. Survival 
time for AD-DS does not differ much from that for late-onset AD (LOAD), with estimates 
varying between 3.5 years (s.d 2.2)34 and 6.24 years (s.d. 4.1)6. However, individuals with 
severe intellectual disability and dementia were found to have a longer survival time after 
diagnosis than those with milder intellectual disability6, further suggesting that reduced 
brain reserve does not accelerate disease progression in AD-DS.
Thus, people who have DS are at a greatly increased risk of developing dementia, with 
approximately 70% of individuals developing the condition by the age of 65. However, 
unlike the situation for LOAD, gender and cognitive reserve do not seem to influence AD-
DS onset.
Clinical features of AD-DS
The early symptoms of AD-DS include features that are typical of other forms of AD, such 
as a decline in memory and language skills that may be present several years before 
dementia is diagnosed35–37. However, changes in personality and behaviour are more 
common in the early stages of AD-DS than they are in other forms of AD: individuals 
typically display either apathy, lack of motivation and stubbornness, or increasing 
behavioural excesses and impulsivity. These ‘non-cognitive’ changes (also referred to as 
behavioural and psychological symptoms of dementia (BPSDs))38–42 are associated with 
deficits in executive functioning and with the frontal atrophy that is visible on MRI scans, 
which may indicate frontal lobe dysfunction40,43. These changes may be related to pre-
existing deficits in the integrity of the frontal tracts that have been observed in individuals 
with DS44 and that may be worsened by Aβ deposition in the frontal lobes45. Although 
BPSDs are very prominent in early AD-DS, this presentation is not unique to these 
individuals — it also occurs, albeit at lower rates, during the early stages of LOAD46 and 
EOAD47, particularly in cases arising from mutations in the AD risk gene presenilin 1 
(PSEN1; which maps to chromosome 14). Further studies are required to determine the 
earliest changes associated with the development of dementia in people who have DS, and to 
delineate other clinical differences between AD-DS, LOAD and familial forms of EOAD, 
such as the frequencies of co-morbidities that may affect the onset and progression of 
dementia (for example, cardiovascular disease and systemic infections).
Another feature of AD-DS is the more-frequent and earlier appearance of neurological 
symptoms such as gait disturbance and seizures19 when compared with LOAD. Although 
heterogeneous, seizures associated with AD-DS often initially present with myoclonic jerks 
before progressing to tonic–clonic seizures and later to non-epileptic myoclonus with 
cerebellar signs; electroencephalograms show diffuse slowing and spike-and-wave 
patterns48–50. In individuals with LOAD, both complex partial and tonic–clonic seizures 
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have been reported to be the predominant type51,52. Although seizures are reported to occur 
in 0.5–64% of people with LOAD51, more-recent population studies have suggested that 
seizure incidence in LOAD is relatively low, occurring in <5% of cases of the disease53. By 
contrast, most people with AD-DS eventually develop seizures, and a sudden onset of 
seizures in older adults with DS is highly suggestive of AD. Co-morbid seizures are 
associated with a more-aggressive course of AD-DS54 and a greater dementia-associated 
mortality rate6. The mechanism underlying this striking clinical feature of AD-DS is not 
understood, and the study of this may provide significant insights into neurodegeneration, in 
particular how changes in neuronal structure and organization affect disease progression.
Similarly to other forms of AD, the decline through middle-stage AD-DS dementia 
progressively affects more cognitive domains and results in symptoms such as dyspraxia, 
increasing incontinence and pathological grasping and sucking reflexes55,56, as well as 
symptoms of parkinsonism22. In summary, BPSDs may be an important early feature of 
AD-DS, and seizures are commonly associated with AD-DS. However, further comparative 
and mechanistic studies are required to unravel the importance of these clinical observations.
Neuropathological changes in AD-DS
The similarity between the neuropathological changes that occur in AD-DS and those that 
characterize AD in other individuals was first noted in 1929 (REF. 57) and was important 
for the widespread recognition of dementia in people who have DS. This discovery also had 
a key role in the identification of Aβ as the major constituent of amyloid plaques58, the 
identification of the first AD gene, APP59, and the subsequent development of the amyloid 
cascade hypothesis60.
The overall distribution and biochemical composition of plaques (largely composed of Aβ) 
and NFTs (largely composed of tau protein (encoded by microtubule-associated protein tau 
(MAPT))) in people who have DS, EOAD and LOAD are similar58,61–63. However, a greater 
deposition of plaques and tangles occurs in the hippocampus in AD-DS than in EOAD64 
and, consistent with this, histological studies suggest that the earliest Aβ deposition in AD-
DS occurs in the hippocampus65, whereas in LOAD the earliest deposition occurs in the 
basal cortex66. Furthermore, a lower density of Aβ plaques has been reported in the cortex in 
AD-DS than in LOAD64,67,68. These differences may relate to amyloid plaques in AD-DS 
having a more amorphous morphology and a larger average size than those present in 
LOAD69,70, resulting in a lower density caused by the presence of fewer but larger plaques. 
In addition, the aggregation kinetics of Aβ may differ in people with DS because of a higher 
concentration of the peptide resulting from their additional copy of APP. Alternatively, 
differences in plaque load may result from the neurodevelopmental differences that occur in 
people who have DS, resulting in changes in synaptic activity, which is known to regulate 
Aβ production71.
In AD-DS, intracellular accumulation of Aβ precedes extracellular plaque accumulation72–75 
but becomes less prominent in older individuals with extensive pathology, as also observed 
in LOAD76. Additionally, in AD-DS, diffuse plaques composed of non-fibrillary deposits of 
Aβ develop before those with dense cores that are composed of amyloid (Supplementary 
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information S2(table))34,64,65,73,74,77–88. Diffuse plaques are typically not associated with 
other forms of neuropathology, such as activated glial cells or synaptic loss, whereas dense-
core plaques are often associated with dystrophic neurites and activated astroglia and 
microglia89. Also, Aβ42 — a form of Aβ that has a high tendency to aggregate — 
accumulates before deposition of Aβ40 in AD-DS73,74,80, which is consistent with the higher 
abundance of Aβ42 reported in plaques in other forms of AD89. Cerebral amyloid angiopathy 
(CAA) — the deposition of Aβ within cerebral blood vessels — is also observed in older 
individuals with DS74,80,87,90. However, unlike in LOAD, infarcts64 and vascular dementia 
seem to be rare in AD-DS91, although cases of CAA-associated cerebral haemorrhage have 
been described92–95.
In contrast to the findings of the histological studies described above, in vivo amyloid 
imaging by positron emission tomography (PET) indicates that the earliest site of Aβ 
accumulation in AD-DS, as in EOAD, could be the striatum96 and that enhanced deposition 
may occur in the frontal and parietal cortex97. This discrepancy may be because amyloid 
imaging recognizes only a subset of Aβ aggregates, thus not all deposition may be 
detected98. Nonetheless, most individuals with DS have amyloid-positive PET scans by the 
age of 50 (REFS 45,96,99,100). Amyloid load, as measured by PET, does not correlate well 
with cognitive function in adults who have DS in cross-sectional studies45,99, highlighting 
the importance of factors other than amyloid in the development of dementia. However, 
longitudinal imaging studies in this population have yet to be undertaken and may be highly 
informative45,99.
No NFTs have been reported in AD-DS in the absence of dense-core plaque pathology, 
which is consistent with the predictions of the amyloid cascade hypothesis. The density of 
NFTs triples between the fourth and fifth decade of life in AD-DS77, mirroring the onset of 
dementia, and NFT formation rather than amyloid deposition correlates best with cognitive 
decline34, which is consistent with similar findings in LOAD. Thus, changes in tau may 
result in neuronal dysfunction in both AD-DS and LOAD. Interestingly, smaller relative 
changes in nucleolar volume and a trend of reduced cell loss have been reported in the 
cortex and locus coeruleus in AD-DS compared with LOAD, despite comparable NFT 
loads, although similar cell loss was observed in other brain areas68. This may reflect a 
differential response of the trisomic CNS to accumulation of aggregated tau — suggesting, 
intriguingly, that chromosome 21 could encode a gene (or genes) that is neuroprotective 
when triplicated. Further study is required to determine whether trisomy 21 may provide 
protection from neurodegeneration.
As with people in the euploid population, people who have DS may have extensive amyloid 
deposition but no clinical signs of dementia (FIG. 1). Understanding how pathological 
changes due to AD relate to cognitive dysfunction is therefore a key research challenge. 
Identifying the processes that cause an amyloid-laden brain to convert from cognitively 
intact to impaired is crucial for understanding and successfully treating AD. As people who 
have DS develop amyloid deposition and NFTs by the age of 40, study of this group of 
individuals is likely to provide an important insight into the factors that cause dementia. 
Indeed, observations of AD-DS neuropathology already underpin our mechanistic 
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understanding of AD, providing a detailed sequence of pathological changes and how these 
may relate to changes in cognition.
Pathological features other than plaques and NFTs also develop in both AD-DS and LOAD. 
Neuronal accumulation of ubiquitylated and aggregated transactive response DNA-binding 
protein 43 (TDP43; also known as TARDBP) in the cytoplasm and neurites is similar in 
AD-DS (7–14% of cases) and familial AD (10–14% of cases), whereas TDP43 
neuropathology occurs more frequently in LOAD (29–79% of cases), perhaps because of the 
later disease onset101,102. Lewy bodies, particularly in the amygdala, occur at a similar 
frequency in AD-DS and LOAD103, but dementia with Lewy bodies (DLB), which is 
characterized by cognitive decline with hallucinations and parkinsonism features, is rare in 
DS104. Granulovacuolar degeneration, the formation of electron-dense granules in double-
membrane-bound cytoplasmic vacuoles, associated with plaque and NFT pathology occurs 
at a similar frequency in AD-DS and AD64. How this pathology relates to the very early 
endosomal abnormalities that are reported to occur before birth in individuals with DS105 is 
unclear and warrants further investigation. Recent AD-related genome-wide association 
studies have highlighted the importance of the endosomal system in LOAD106, indicating 
that this system may be of particular significance to disease.
AD-DS versus Dup-APP-associated AD
Dup-APP is a rare cause of familial EOAD, and comparison with AD-DS yields 
pathogenetic insights, as an additional copy of APP is present in both diseases. They 
therefore differ from other forms of familial AD that are the result of mutations in APP, 
PSEN1 or PSEN2 that modulate the processing of APP and the generation of Aβ. In Dup-
APP, regions of chromosome 21 triplication vary in size8–15,47,107,108 (FIG. 2); the smallest 
known duplication contains only an additional copy of APP and no other coding genes8. By 
contrast, in AD-DS, triplication of any chromosome 21 gene in addition to APP may 
modulate the development of dementia. Studying these genes may therefore provide novel 
insights into AD mechanisms.
The age of onset of dementia in individuals with Dup-APP ranges from 39 to 64 years 
(mean age ~52 years), and dementia shows virtually complete penetrance by the age of 65 
years. By contrast, there is a broad variation in age of onset in AD-DS, and many individuals 
present with significant cognitive decline only after the age of 55 years, or even escape it 
altogether. This is remarkable given the usual co-morbid health issues and relative lack of 
brain reserve in individuals with DS. Thus, a possible protective mechanism (or 
mechanisms) from triplication of an unknown gene (or genes) on chromosome 21 may be 
important for resistance to dementia in people with DS. Moreover, intracerebral 
haemorrhage (ICH) is common in individuals with Dup-APP (occurring in 20–50% of 
cases)9–14,47,108, whereas individuals with DS are generally protected from this pathology, 
with only occasional reports. Thus, triplication of a chromosome 21 gene (or genes) may 
protect against some AD co-morbidity, and further comparative study of AD-DS and Dup-
APP is required to understand the mechanisms underpinning this observation.
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The few histopathological Dup-APP studies that have been carried out report diffuse atrophy 
with associated neuronal loss, deposition of plaques, CAA and accumulation of 
intraneuronal Aβ40 and NFTs11,109, and this pathology seems to be similar to AD-DS 
pathology (Supplementary information S3 (table)). However, further studies are 
needed75,109. Clinical DLB and cortical Lewy bodies have been observed in a few 
cases11,13,109, but currently there are insufficient data on these phenotypes to compare Dup-
APP with AD-DS or LOAD. As in AD-DS, there is a greatly increased risk of dementia-
associated seizures in Dup-APP10–13,47, in contrast to LOAD, in which seizures are 
relatively rare. This suggests that duplication of APP, and possibly of other genes located 
nearby, could be epileptogenic; however, as late-onset seizures often follow onset of 
dementia, they may also be related to synaptic deterioration that results in abnormal 
synchronization of neuronal networks and hyperexcitability110.
Genes and mechanisms in AD-DS
The presence of three copies of a dosage-sensitive gene (or genes) on chromosome 21 
results in greatly enhanced risk of AD. Chromosome 21 carries 233 coding genes, 299 long 
non-coding genes (Ensembl release 78) and 29 microRNAs (miRBase release 21)111; thus, 
one or more of these must have a key role in AD. The phenotype resulting from a dosage-
sensitive gene depends on the number of copies of the gene in the genome. However, not all 
genes are dosage sensitive, as homeostasis often prevents a gene from being overexpressed 
and the regulation of expression is often dependent on environmental context112. 
Furthermore, trisomy 21 causes widespread transcriptional dysregulation112,113, which may 
be the result of aneuploidy rather than of triplication of a specific gene. The importance of 
this in AD-DS remains unclear. Finally, acceleration of the epigenetic changes associated 
with ageing occurs in the DS brain114 — whether this alters gene expression or modulates 
the development of AD is an important area for future study.
The development of neuropathology and dementia varies significantly between individuals 
with DS, and understanding the factors (genetic or environmental) that cause this variation is 
likely to provide key insights into disease mechanisms. Below, we describe the genes that 
are currently implicated in the development of AD-DS and highlight the importance of 
further study of the genetics of AD-DS to understand how variation in the whole genome 
influences the development of disease.
Triplication of APP
The key dosage-sensitive gene for AD-DS is likely to be APP, as an additional normal copy 
of this gene is sufficient to cause EOAD in the absence of trisomy of the rest of chromosome 
21 (REFS 8–15,47,107). The additional copy of APP in DS does not typically cause 
substantial Aβ accumulation until the second or third decade of life, although amyloid 
pathology has been demonstrated in a few childhood post-mortem examinations (BOX 1; 
FIG. 1). This lack of early Aβ accumulation may be due to APP not becoming dosage 
sensitive until adulthood, as suggested by both mouse and human studies115–117. However, 
increased levels of soluble Aβ42 are found in ~50% of trisomy 21 fetal brains118, suggesting 
that APP may be dosage sensitive during fetal development of individuals with DS but that 
this change may not be sufficient to cause extensive Aβ deposition in the developing brain 
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— perhaps because of efficient clearance. Consistent with this, overexpression of APP 
and/or increased levels of Aβ have been reported in trisomy 21 human cell models, 
including in induced pluripotent stem cells (iPSCs) derived from infants or young adults 
with DS119–122. Although triplication of APP does not necessarily lead to enhanced 
expression of APP and subsequent increase in Aβ accumulation in all contexts, 
overexpression of APP is strongly linked to Aβ deposition in adult life. Thus, elucidating the 
factors that control the regulation of APP expression will considerably aid our understanding 
of AD.
Interaction of other chromosome 21 genes with APP
Several proteins encoded by other chromosome 21 genes have been suggested to modulate 
APP processing and Aβ generation (BOX 2; FIG. 3). For example, the transcription factor 
ETS2 is thought to transactivate the APP promoter, leading to overexpression123. The 
chromosome 21-encoded proteins small ubiquitin-related modifier 3 (SUMO3) and dual-
specificity tyrosinephosphorylation-regulated kinase 1A (DYRK1A) modify APP post-
translationally, which may alter Aβ generation124–126. Additionally, the chromosome 21 
microRNA miR-155 has been suggested to modulate γ-secretase activity and hence the 
processing of APP, through its effect on the expression of sorting nexin 27 (REF. 127). 
Moreover, the β-secretase responsible for processing APP, β-site APP-cleaving enzyme 1 
(BACE1), has a homologue, BACE2, encoded on chromosome 21, which may influence the 
onset of dementia in people with DS128. BACE2 does not have β-secretase activity, and in 
fact cleaves APP on the carboxy-terminal side of the β-secretase cut site within the Aβ 
region, preventing generation of the peptide. Thus, enhancing BACE2 expression may be 
protective against accumulation of Aβ129. However, BACE2 overexpression does not alter 
Aβ accumulation in a mouse model130, and the protein does not seem to have enhanced 
expression in the adult DS brain115,131. Whether triplication of any chromosome 21 gene 
alters APP biology sufficiently to modulate the development of AD remains to be 
determined.
Genes involved in LOAD
Polymorphisms in genes with important functions in LOAD have similar roles in the 
development of AD-DS; for example, the apolipoprotein E (APOE) ε4 allele is associated 
with greater Aβ deposition, as well as with earlier onset and increased risk of AD-DS, 
whereas the APOE ε2 allele leads to reduced Aβ deposition and a lower risk of 
disease132–138. Similarly, variants of phosphatidylinositol-binding clathrin assembly protein 
(PICALM) and sortilin-related receptor 1 (SORL1) influence age of onset in AD-DS, as they 
do in LOAD132,139,140, further supporting the theory that common mechanisms underlie 
both diseases. Whether variation in other genes with a role in LOAD is also important for 
AD-DS remains to be determined and is an important area for future study. Large-scale 
study of the genetic variants that contribute to the onset of dementia in AD-DS will provide 
an opportunity to gain insights into the mechanisms that underpin variation in the onset of 
dementia.
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Disruption of secretory and endosomal systems
The earliest site of Aβ accumulation in AD-DS is within the neuron72–75, indicating that 
secretory and endosomal systems are central to Aβ generation. Moreover, an extra copy of 
APP is sufficient to cause endosomal enlargement and intracellular trafficking defects141,142 
via an Aβ-independent mechanism143. Enlargement of endosomes in trisomic neurons may 
cause axonal trafficking defects that contribute to neuronal degeneration141.
Triplication of chromosome 21 genes other than APP may also affect the secretory–
endosome system, thereby affecting synaptic function, Aβ production and Aβ clearance. 
Small segmental duplications of the chromosome 21 endosome-to-Golgi-trafficking gene 
DOPEY2 (REF. 144) have been associated with LOAD and mild cognitive 
impairment14,145, although this was not replicated in an independent study146. A reduction 
in the dose of the chromosome 21 gene cystatin B (CSTB), which encodes an endogenous 
inhibitor of lysosomal cathepsins, decreases the accumulation of Aβ and associated 
cognitive deficits147. Overexpression of another chromosome 21 gene, synaptojanin 1 
(SYNJ1), which encodes a phosphoinositide phosphatase that regulates levels of membrane 
phosphatidylinositol-4,5-bisphosphate, has been associated with endosomal enlargement148, 
whereas reduced expression of SYNJ1 lowers Aβ accumulation, as well as neuronal 
dysfunction and cognitive deficits149,150. How endosomal enlargement caused by trisomy 
contributes to neuronal dysfunction and degeneration is another important area for future 
research.
Mitochondria and ROS
Mitochondrial dysfunction and enhanced production of reactive oxygen species (ROS) occur 
in people with DS and in trisomy 21 models151–154, and may contribute to the accelerated 
ageing reported in people who have DS155. Mitochondrial impairment may directly affect 
energy-hungry synapses, contributing to cognitive deficits156. Moreover, increased levels of 
ROS make trisomic neurons more prone to undergoing apoptosis, potentially making them 
more likely to degenerate151. Trisomy 21-associated increases in ROS levels may alter APP 
processing, promoting intracellular accumulation of Aβ119,151. Thus, protecting the trisomic 
brain from ROS may be of therapeutic value, although antioxidant supplementation has 
failed to show efficacy in preventing dementia in this population157. Interestingly, 
superoxide dismutase 1 (SOD1), which has a key role in processing ROS, lies on 
chromosome 21, and upregulation of SOD1 seems to protect against APP and Aβ 
neurotoxicity158, perhaps by modulating Aβ oligomerization159. Consistent with this, higher 
SOD1 enzymatic activity correlates with better memory in adults with DS160. However, 
increased SOD1 activity has also been suggested to cause accelerated cell senescence by 
increasing the levels of hydrogen peroxide, a form of ROS161.
Neuronal development and function
Several processes are likely to contribute to the intellectual disability associated with DS. 
These include a reduction in the numbers of neurons and dendritic spines, dendritic 
arborization, an alteration in the excitatory–inhibitory balance and a global impairment in 
network connectivity68,162–166. These perturbations in the structure, function and 
organization of the CNS may profoundly affect its degeneration in AD-DS (BOX 1). 
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Triplication of several chromosome 21 genes contributes to changes in neurodevelopment 
and/or neuronal function. For example, ubiquitin-specific peptidase 16 (USP16) or 
DYRK1A upregulation alters stem cell fate167–169, which may in turn alter neuronal 
differentiation. Additionally, overexpression of several chromosome 21 genes (for example, 
the microRNA gene mir-155 and the protein-coding genes SYNJ1, regulator of calcineurin 1 
(RCAN1), intersectin 1 (ITSN1) and DS cell adhesion molecule (DSCAM)) has been 
implicated in deficits in synaptic structure and function148,170,171. These genes may also 
play a part in AD-DS, perhaps via an effect on APP processing or on cognitive reserve. APP 
overexpression may also affect CNS function independently of the production and 
accumulation of Aβ, because the expression level of full-length APP influences 
neurogenesis, neuronal migration, axonal growth and the maintenance of the excitatory–
inhibitory balance172,173. How the changes in CNS function caused by trisomy of 
chromosome 21 affect neurodegeneration in AD-DS is little understood and is a crucial area 
of future research.
Intracellular signalling and tau
Perturbations in intracellular signalling associated with trisomy 21 (REF. 174) may affect 
the response of the CNS to pathological changes. For example, overexpression of the 
chromosome 21 genes RCAN1 and DYRK1A promotes aberrant phosphorylation of 
tau152,175–177. DYRK1A is dosage sensitive in the adult brain178, and overexpression of this 
gene modulates tau splicing, altering the relative abundance of tau with three or four 
microtubule-binding domains (3-repeat (3R) and 4R tau, respectively), which may affect the 
formation of NFTs179,180. Consistent with this, an increase in the ratio of 3R/4R tau has 
been reported to occur in AD-DS, as compared with LOAD or age-matched euploid 
individuals without dementia179,180. Additionally, an increase in the total amount of tau has 
been reported in the cortex in AD-DS as compared with that in age-matched euploid 
individuals without dementia, and in DS iPSC-derived neurons122,179; this upregulation may 
be the result of increased APP levels181. DYRK1A also downregulates the levels of neural 
restrictive silencing factor (NRSF; also known as REST), a neuroprotective protein168,169, 
which has reduced expression in people with AD182. Variants in DYRK1A have been 
associated with risk of LOAD183, further indicating a possible role in disease pathogenesis, 
although this association was not replicated in an independent study184.
Cholesterol metabolism
Alterations in cholesterol metabolism may contribute to the development of dementia31. 
Total cholesterol levels have been suggested to predict the onset of dementia in people with 
DS, particularly in those individuals who have an APOE ε4 allele28. Clinical trials are 
therefore underway to determine whether statins can prevent decline in older adults with DS, 
which may provide both clinical and mechanistic insights185. The chromosome 21 lipid 
transporter ATP-binding cassette G1 (ABCG1) has been suggested to regulate cholesterol 
efflux and may alter cholesterol metabolism in people with DS186. Whether trisomy of this 
gene is related to the development of AD-DS remains unclear, as ABCG1 overexpression 
has been reported both to increase and to decrease Aβ generation in vitro187,188 and does not 
change Aβ accumulation in vivo189, suggesting that this gene may not be associated with the 
development of AD-DS. Further study is required to understand the mechanisms that 
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underlie the link between increased cholesterol levels and the onset of dementia in 
individuals with DS.
Immune system dysfunction
Growing evidence shows that the immune system plays an important part in the 
development of AD106,190. Individuals with DS are at an increased risk of immune system 
dysfunction: these individuals have a higher incidence of both autoimmune and infectious 
disease191, and show upregulation of pro-inflammatory makers, including interleukin-1, in 
the brain192,193. This dysregulation may contribute to AD-DS through alterations in micro-
glial activation190. Microglia in AD-DS have been reported to be associated with both 
mature Aβ plaques194 and NFTs195, although the contribution of the immune response to 
AD-DS has yet to be fully explored. The chromosome 21 gene S100 calcium-binding 
protein beta (S100B) is expressed in astrocytes and is upregulated in both AD196 and AD-
DS192, and it may contribute to neurodegeneration by promoting Aβ deposition197 and tau 
phosphorylation198 and by creating a neurotoxic environment through the release of 
extracellular signals199.
Translational research
The life expectancy of people with DS is increasing because of better health care and 
improved social inclusion. However, as with the euploid population, ageing brings new 
issues; in people with DS, a major ageing-related issue is a vastly increased risk of EOAD. 
People who have DS develop amyloid plaques and NFTs by the age of 40 years, and many 
individuals subsequently go on to develop dementia. Despite genetic and Aβ differences 
between the various forms of EOAD and LOAD, many similarities in disease process are 
observed such that AD seems to converge on common mechanisms of pathology. Thus, in 
the AD-DS patient population, it is feasible both to determine the factors (genetic and/or 
environmental) that cause conversion from pathological disease to cognitive decline and to 
undertake intervention trials to halt the development of dementia.
As APP gene dosage is the major determinant of AD-DS, it follows that therapies aimed at 
reducing Aβ (such as BACE inhibition or Aβ immunization) might have a beneficial effect 
in the DS population. Such approaches are being trialled for people with familial AD arising 
from APP or PSEN1 mutations200, and similar clinical trials in AD-DS could provide 
valuable additional insight, given the predictable conversion to AD neuropathology and 
subsequent dementia in this population. Other treatment options that require further 
development include DYRK1A inhibitors and ROS modulators. Notably, treatment safety is 
of particular importance because many individuals with DS are unable to consent to their 
own participation in clinical trials and because they will probably need to undergo treatment 
for many years.
Conclusions
Many questions remain to be answered in AD-DS, including, most importantly, the 
mechanisms underlying the later onset of dementia as compared with Dup-APP, how 
neurodevelopmental perturbations affect neurodegeneration and the identity of any 
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chromosome 21 gene (or genes) that may protect against dementia. We now have a 
remarkable set of tools for studying AD-DS, ranging from new model systems to genomics 
studies. Although there are undoubtedly specific problems in both analysing and treating 
people who have DS for AD, such as issues of informed consent, trisomy 21 is an extremely 
important disorder for learning about the development of neurodegeneration and for testing 
potential therapeutic strategies to the benefit of everyone at risk of AD.
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Glossary
Dyspraxia Disrupted fine or gross motor coordination.
Early-onset 
Alzheimer disease
(EOAD). Occurrence of Alzheimer disease before the age of 65 
years.
Euploid Having a normal chromosome number (46 chromosomes in 23 
pairs in humans).
Executive 
functioning
Mental processing skills involving the frontal cortex; used for 
planning, attention focusing, working memory, mental flexibility 
and self-control.
Incidence The rate of new occurrences of a disorder within a specified period 
of time.
Lewy bodies Protein aggregates typically containing α-synuclein.
Myoclonic jerks Brief involuntary muscle twitches that are a medical sign of various 
neurological disorders.
Parkinsonism A clinical syndrome including bradykinesia (slow movements), 
muscle rigidity and tremor, often due to the neurodegenerative 
condition Parkinson disease but also associated with other 
neurological conditions, toxins and medications.
Prevalence The number of cases of a disorder at one time within a population.
Tonic–clonic 
seizures
A common type of epileptic seizure with a tonic phase (stiffening 
of muscles and loss of consciousness) followed by a clonic phase 
(rapid, rhythmic jerking of arms and legs).
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Box 1
Identifying risk and protective factors for AD in young children
It may seem counterintuitive to study infants and young children to understand a disease 
that presents only in adulthood. However, Alzheimer disease (AD) does not have an 
abrupt onset but emerges from a lengthy developmental trajectory in which precursors 
(for example, prodromal changes) surface well before overt dementia symptoms. Several 
genes involved in neurodevelopment have been suggested to have an important role in 
AD (including components of the WNT and reelin signalling pathway201,202). 
Additionally, cultures of cells derived from infants with Down syndrome (DS) show 
clear overexpression of amyloid precursor protein (APP)119–122, and amyloid-β (Aβ) 
plaques have been found in the brains of children with DS who are as young as 8 years of 
age65. Thus, the syndrome offers a longitudinal perspective on the multilevel effects of 
Aβ and tau pathology during development.
DS is diagnosed prenatally or at birth, and all infants with DS are at a significantly 
increased risk of subsequently developing AD, although not all will present with 
dementia, even as ageing adults. It is possible that in adults with DS, patterns of 
individual differences between those with AD and those without AD are already rooted 
in their individual differences when they are just infants, at the genetic, cellular, neural, 
cognitive, behavioural, sleep and/or environmental levels. The challenge is to identify 
individual differences in childhood that pinpoint risk and protective factors for 
subsequent AD outcome in adulthood. We can then identify biomarkers and devise early 
intervention strategies, initially for individuals with DS and subsequently for members of 
the euploid population, revolutionizing our understanding of the pathways that lead to 
AD. Thus, a developmental approach is essential, especially as it has already been shown 
that differences that can be observed in infancy in individuals with DS (for example, in 
the simple planning of saccadic eye movements) have cascading effects on cognitive 
outcomes in childhood and adulthood (for example, on numerical processing, language 
and face processing)203. Therefore, to fully comprehend AD in adults, it is crucial to 
study its full developmental trajectory, and understanding DS makes this possible.
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Box 2
Modelling AD-DS in mice and in human iPSCs
Amyloid precursor protein (APP) overexpression in mouse models causes dysfunction of 
basal forebrain cholinergic neurons and synaptic and behavioural changes141,204–206. 
However, increased expression of wild-type APP, even at levels in excess of those 
present in Down syndrome (DS), is insufficient to cause extensive Alzheimer disease 
(AD) neuropathology207. Only mice expressing mutant APP and/or other AD-associated 
genes recapitulate aspects of AD neuropathology and/ or cognitive change207. Similarly, 
although altered expression of many chromosome 21 genes modifies mouse models of 
familial AD, whether a single extra copy of these genes is sufficient to affect pathology 
and behaviour remains unclear. However, chromosome engineering, which enables the 
generation of mouse models with large genomic duplications, may help to elucidate the 
effects of trisomy on neurodegeneration208.
Reprogramming human somatic cells into induced pluripotent stem cells (iPSCs; which 
are in an embryonic stem cell-like state) is revolutionizing AD modelling, and advances 
in three-dimensional differentiation now permit the development of extensive amyloid-β 
(Aβ) and tau pathology in vitro. Comparisons have been made between euploid and 
trisomy 21 iPSCs derived from multiple sources, including different individuals (non-
isogenic)122,209; isogenic lines generated in cell culture, spontaneously or by 
selection154,210; lines in which one of the three copies of chromosome 21 has been 
silenced211; monozygotic twins that were discordant for trisomy 21 (REF. 169); and non-
integration-reprogrammed isogenic lines from an adult with mosaic DS (a condition in 
which only a percentage of an individual’s cells carry an extra copy of chromosome 
21)121. Neurons derived from iPSCs show cellular phenotypes underpinning AD 
pathology, such as increased Aβ production, abnormal subcellular distribution of 
phosphorylated tau, mitochondrial abnormalities and accelerated cellular 
ageing121,122,154,212. DS iPSC models can be used to dissect the effect of trisomy of 
individual chromosome 21 genes (for example, by genome editing using clustered 
regularly interspaced short palindromic repeat–CRISPR-associated protein 9 (CRISPR–
Cas9) technology), to develop high-throughput screening assays for phenotype-correcting 
compounds and to investigate cellular phenotypes in iPSCs generated from individuals 
with DS with very early versus very late ages of onset of dementia.
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Figure 1. Development of pathology and dementia in AD-DS and Dup-APP
The graphs show the cumulative frequency of amyloid plaque deposition (measured using 
histological methods and positron emission tomography with Pittsburgh compound B (PiB), 
a radioactive analogue of thioflavin that binds to amyloid) and neurofibrillary tangle (NFT) 
development (measured using histological methods), and the cumulative frequency of 
dementia in people with Alzheimer disease and Down syndrome (AD-DS)6,33 and in 
individuals with familial AD induced by duplication of amyloid precursor protein (Dup-
APP). As shown, people who have DS can live for many years with substantial amyloid 
deposition before the development of dementia. Solid lines are based on the data described 
in Supplementary information S1–S3 (tables). Dashed lines indicate hypothesized 
development of pathology for which there are currently no data available. Further 
pathological and clinical studies directly comparing these two populations are required to 
verify the apparent differences in clinical dementia onset and to determine whether the 
development of pathology differs from that proposed here. Aβ, amyloid-β.
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Figure 2. Regions of chromosome 21 duplicated in Dup-APP EOAD and ICH
Schematic illustrating the genetic regions affected in reported cases of early-onset 
Alzheimer disease (EOAD) accompanied by duplication of amyloid precursor protein (Dup-
APP)8–15,108. The minimal duplicated region is shown in blue: the only gene duplicated in 
all cases is APP. ADAMTS1, a disintegrin and metalloproteinase with thrombospondin 
motifs 1; ATP5J, ATP synthase-coupling factor 6; BACH1, BTB and CNC homologue 1; 
BTG3, BTG family member 3; C21orf91, chromosome 21 open reading frame 91; CCT8, 
chaperonin containing TCP1 8; CHODL, chondrolectin; CLDN17, claudin 17; CXADR, 
coxsackie virus and adenovirus receptor homologue; CYYR1, cysteine- and tyrosine-rich 1; 
GABPA, GA repeat-binding protein-alpha; GRIK1, glutamate receptor ionotropic, kainate 1; 
HSPA13, heat shock protein 70 kDa 13; ICH, intracerebral haemorrhage; JAM2, junction 
adhesion molecule 2; LIPI, lipase member I; LTN1, listerin E3 ubiquitin protein ligase 1; 
MAP3K7CL, MAP3K7 carboxy-terminal like; MRPL39, mitochondrial ribosomal protein 
L39; N6AMT1, N-6 adenine-specific DNA methyltransferase 1; NCAM2, neural cell 
adhesion molecule 2; NRIP1, nuclear receptor-interacting protein 1; PED, pedigree; 
POTED, POTE ankyrin domain family member D; RBM11, RNA-binding motif protein 11; 
RWDD2B, RWD domain-containing 2B; SAMSN1, SAM domain, SH3 domain and nuclear 
localization signals 1; TMPRSS15, transmembrane protease serine 15; USP, ubiquitin-
specific peptidase.
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Figure 3. Schematic of suggested mechanisms that are important in AD-DS and their related 
genes
Several genes may modulate processes that are relevant to the development of Alzheimer 
disease in people with Down syndrome (AD-DS); these include non-chromosome 21 genes, 
such as apolipoprotein E (APOE; which could alter disease by influencing cholesterol 
metabolism and possibly many other pathways), phosphatidylinositol-binding clathrin 
assembly protein (PICALM), sortilin-related receptor 1 (SORL1; which may influence 
disease via the endocytosis system and amyloid precursor protein (APP) processing) and 
microtubule-associated protein tau (MAPT). Tau aggregates to form neurofibrillary tangles 
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(NFTs). Numerous chromosome 21 genes have also been suggested to influence the 
development of AD-DS, including genes that may influence APP processing and synaptic 
function via their role in the secretory–endosome system (including cystatin B (CSTB), 
DOPEY2, synaptojanin 1 (SYNJ1), intersectin 1 (ITSN1) and the microRNA gene mir-155), 
APP processing (including small ubiquitin-like modifier 3 (SUMO3), ETS2 and beta-site 
APP-cleaving enzyme 2 (BACE2)), cholesterol metabolism (including ATP-binding cassette 
G1 (ABCG1)), cellular signalling and tau phosphorylation (including dual-specificity 
tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and regulator of calcineurin 1 
(RCAN1)), inflammation (including mir-155 and S100 calcium-binding protein beta 
(S100B)), synaptic function (including DOPEY2, SYNJ1, ITSN1, RCAN1 and mir-155), 
neurodevelopment (including ubiquitin-specific peptidase 16 (USP16), DYRK1A and DS 
cell adhesion molecule (DSCAM)) and oxidative stress (superoxide dismutase 1 (SOD1)). 
The relative importance of these processes to the development of dementia in AD-DS 
remains unclear and constitutes an area for future study. Chromosome 21 genes and gene 
products are shown in purple; non-chromosome 21 genes and gene products are shown in 
green. Aβ, amyloid-β.
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